Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of SHP640 vs Povidone Iodine and Placebo in Adenoviral Conjunctivitis
2016-002439-14Phase 3Terminated
- Sponsor
- Takeda
- Start
- Aug 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexamethasone + povidone-iodine in adenoviral conjunctivitis (3 arms), sponsored by Takeda. Primary endpoint: Primary endpoint: clinical resolution at Day 6. Started Aug 2017; status: terminated.
02
Drugs
dexamethasone + povidone-iodine
03
Conditions
adenoviral conjunctivitis
Beyond the preview
Go deeper on 2016-002439-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002439-14.